Trial of early start pramipexole in Parkinson's disease

被引：0
|
作者：
Schapira, A.
Davidai, G.
Cappola, J.
Marek, K.
机构：
来源：
MOVEMENT DISORDERS | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P511
引用
收藏
页码：S466 / S466
页数：1
相关论文
共 50 条
  • [41] BUDGET IMPACT ANALYSIS OF PRAMIPEXOLE EXTENDED RELEASE MONOTHERAPY IN EARLY PARKINSON'S DISEASE
    Belousov, D.
    Afanasieva, E.
    VALUE IN HEALTH, 2015, 18 (07) : A752 - A753
  • [42] Cost-effectiveness of pramipexole compared with piribedil in early Parkinson's disease patients
    Chikina, ES
    Gusev, EL
    Belousov, YB
    Guecht, AB
    VALUE IN HEALTH, 2005, 8 (03) : 321 - 321
  • [43] Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
    Hametner, Eva-Maria
    Seppi, Klaus
    Poewe, Werner
    CLINICAL INTERVENTIONS IN AGING, 2012, 7 : 83 - 88
  • [44] Sustained efficacy and tolerability of pramipexole extended-release in early Parkinson's disease
    Poewe, W.
    Barone, P.
    Hauser, R.
    Mizuno, Y.
    Rascol, O.
    Harjula, J.
    Sohr, M.
    Salin, L.
    Shapira, A. H. V.
    MOVEMENT DISORDERS, 2010, 25 (07) : S306 - S306
  • [45] Twice-Daily, Low-Dose Pramipexole in Early Parkinson's Disease: A Randomized, Placebo-Controlled Trial
    Kieburtz, Karl
    MOVEMENT DISORDERS, 2011, 26 (01) : 37 - 44
  • [46] Once-daily extended-release pramipexole in early parkinson's disease: a randomized trial with placebo and active control
    Rascol, O.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 : 17 - 17
  • [47] A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: Design and methods of the CALM-PD study
    Holloway, R
    Shoulson, I
    Fahn, S
    Kieburtz, K
    Lang, A
    Marek, K
    McDermott, M
    Seibyl, J
    Weiner, W
    Welsh, M
    Kamp, C
    Day, D
    Pahwa, R
    Smith, D
    McGuire, D
    Barclay, L
    Sutherland, L
    Hildebrand, K
    Hubble, J
    Weeks, C
    LeWitt, P
    Mistura, K
    Bloomfield, W
    Miyasaki, J
    Duff, J
    Sime, E
    Suchowersky, O
    Argatoff, P
    Andreas, Y
    Kurth, M
    Brewer, M
    Russell, D
    Fussell, B
    Ford, B
    Dillon, S
    Hammerstad, J
    Stone, C
    Riley, D
    Rainey, P
    Standaert, D
    Tennis, M
    Wooten, F
    Rost-Ruffner, E
    Factor, S
    Brown, D
    Jankovic, J
    Beach, J
    Kurlan, R
    Gardiner, I
    Panisset, M
    CLINICAL NEUROPHARMACOLOGY, 2000, 23 (01) : 34 - 44
  • [48] Cost effectiveness of pramipexole in Parkinson's disease in the US
    Hoerger, TJ
    Bala, MV
    Rowland, C
    Greer, M
    Chrischilles, EA
    Holloway, RG
    PHARMACOECONOMICS, 1998, 14 (05) : 541 - 557
  • [49] Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease
    Piedad, John C. P.
    Cavanna, Andrea E.
    PARKINSONS DISEASE, 2012, 2012
  • [50] The benefits of pramipexole selection in the treatment of Parkinson's disease
    Silindir, Mine
    Ozer, A. Yekta
    NEUROLOGICAL SCIENCES, 2014, 35 (10) : 1505 - 1511
12345